PKP2-ACM Natural History Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorRocket Pharmaceuticals Inc.
About this trial
The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.
Eligibility criteria
Qualifiers
None
Disqualifiers
Male or female age 12 years or older at the time of providing informed consent (i.e., ICF provision).
Capable and willing to provide signed informed consent and/or assent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.
Clinical diagnosis of arrhythmogenic cardio myopathy (ACM)
Documentation of a pathogenic or likely pathogenic variant in PKP2 by a CLIA-certified genetic testing laboratory
Trial design
Treatments tested in this trial
- Not listed
Trial groups
36 Participants
are grouped into 1 trial groupLocations
3Netherlands
Amsterdam UMC1105 AZ, Amsterdam Netherlands
United States
Boston Children's Hospital02116, BostonMassachusetts, United States
Duke University27710, DurhamNorth Carolina, United States
Sponsors and collaborators
Rocket Pharmaceuticals Inc.
Lead sponsor
Source ClinicalTrials.gov